Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

Table 4 Change from baseline to end of treatment: lipids, glycemic parameters, body weight and blood pressure

Full analysis population; percentage change from baseline (95% CI)	Aleglitazar 150 μg	Pioglitazone 45 mg
LDL-C*	n = 142	n = 141
LDL-C*	–7.3^† (–13.2, –1.0)	–0.3 (–6.8, 6.6)
HDL-C	n = 142	n = 140
HDL-C	22.0^‡ (17.4, 26.6)	11.6 (6.9, 16.3)
Triglycerides	n = 142	n = 140
Triglycerides	–33.6^‡ (–41.1, –26.1)	–14.1 (–21.7, –6.5)
Safety analysis population; absolute change from baseline (95% CI)	Aleglitazar 150 μg	Pioglitazone 45 mg
HbA1c, %	n = 148	n = 147
HbA1c, %	–0.67 (–0.87, –0.48)	–0.76 (–0.96, –0.56)
FPG, mmol/L	n = 148	n = 147
FPG, mmol/L	–1.96 (–2.38, –1.54)	–1.64 (–2.06, –1.22)
Body weight, kg	n = 149	n = 147
Body weight, kg	2.4 (1.6, 3.2)	2.5 (1.7, 3.3)
Systolic blood pressure, mmHg	n = 149	n = 147
Systolic blood pressure, mmHg	1.7 (–1.0, 4.5)	2.3 (–0.4, 5.1)
Diastolic blood pressure, mmHg	n = 149	n = 147
Diastolic blood pressure, mmHg	–2.2 (–3.9, –0.5)	–0.5 (–2.3, 1.2)

Data show LS mean changes. The last-observation-carried-forward principle was applied to missing values of continuous variables.
CI = confidence interval; FPG = fasting plasma glucose; HbA1c = glycosylated hemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; LS = least squares.
*Analysis on log-transformed scale, geometric means ratio expressed as percentage change.
^†p < 0.05 versus pioglitazone at end of treatment. ^‡p < 0.001 versus pioglitazone at end of treatment.

ISSN: 1471-2369